243 related articles for article (PubMed ID: 34129856)
41. Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling.
Lei S; Meng Q; Liu Y; Liu Q; Dai A; Cai X; Wang MW; Zhou Q; Zhou H; Yang D
Eur J Pharmacol; 2024 Apr; 968():176419. PubMed ID: 38360293
[TBL] [Abstract][Full Text] [Related]
42. Development of novel radioiodinated exendin-4 derivatives targeting GLP-1 receptor for detection of β-cell mass.
Ogawa Y; Kimura H; Fujimoto H; Kawashima H; Toyoda K; Mukai E; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2021 Dec; 52():116496. PubMed ID: 34808404
[TBL] [Abstract][Full Text] [Related]
43. Acute but not chronic activation of brain glucagon-like peptide-1 receptors enhances glucose-stimulated insulin secretion in mice.
Tudurí E; Beiroa D; Porteiro B; López M; Diéguez C; Nogueiras R
Diabetes Obes Metab; 2015 Aug; 17(8):789-99. PubMed ID: 25962313
[TBL] [Abstract][Full Text] [Related]
44. Synthesis, Optimization, and Biological Evaluation of Corrinated Conjugates of the GLP-1R Agonist Exendin-4.
Tinsley IC; Borner T; Swanson ML; Chepurny OG; Doebley SA; Kamat V; Sweet IR; Holz GG; Hayes MR; De Jonghe BC; Doyle RP
J Med Chem; 2021 Mar; 64(6):3479-3492. PubMed ID: 33677970
[TBL] [Abstract][Full Text] [Related]
45. Insulin and IGF-1 receptor autocrine loops are not required for Exendin-4 induced changes to pancreatic β-cell bioenergetic parameters and metabolism in BRIN-BD11 cells.
Rowlands J; Cruzat V; Carlessi R; Newsholme P
Peptides; 2018 Feb; 100():140-149. PubMed ID: 29412813
[TBL] [Abstract][Full Text] [Related]
46. The therapeutic potential of GLP-1 receptor biased agonism.
Jones B
Br J Pharmacol; 2022 Feb; 179(4):492-510. PubMed ID: 33880754
[TBL] [Abstract][Full Text] [Related]
47. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
48. L-dopa-Dependent Effects of GLP-1R Agonists on the Survival of Dopaminergic Cells Transplanted into a Rat Model of Parkinson Disease.
Elabi OF; Davies JS; Lane EL
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830228
[TBL] [Abstract][Full Text] [Related]
49. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
50. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.
Botfield HF; Uldall MS; Westgate CSJ; Mitchell JL; Hagen SM; Gonzalez AM; Hodson DJ; Jensen RH; Sinclair AJ
Sci Transl Med; 2017 Aug; 9(404):. PubMed ID: 28835515
[TBL] [Abstract][Full Text] [Related]
51. Exendin-4 from Heloderma suspectum venom: From discovery to its latest application as type II diabetes combatant.
Yap MKK; Misuan N
Basic Clin Pharmacol Toxicol; 2019 May; 124(5):513-527. PubMed ID: 30417596
[TBL] [Abstract][Full Text] [Related]
52. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
53. A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents.
Mietlicki-Baase EG; Liberini CG; Workinger JL; Bonaccorso RL; Borner T; Reiner DJ; Koch-Laskowski K; McGrath LE; Lhamo R; Stein LM; De Jonghe BC; Holz GG; Roth CL; Doyle RP; Hayes MR
Diabetes Obes Metab; 2018 May; 20(5):1223-1234. PubMed ID: 29327400
[TBL] [Abstract][Full Text] [Related]
54. The glucagon-like peptide-1 receptor agonist, exendin-4, reduces sexual interaction behaviors in a brain site-specific manner in sexually naïve male mice.
Vestlund J; Jerlhag E
Horm Behav; 2020 Aug; 124():104778. PubMed ID: 32450068
[TBL] [Abstract][Full Text] [Related]
55. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
56. The major determinant of exendin-4/glucagon-like peptide 1 differential affinity at the rat glucagon-like peptide 1 receptor N-terminal domain is a hydrogen bond from SER-32 of exendin-4.
Mann RJ; Nasr NE; Sinfield JK; Paci E; Donnelly D
Br J Pharmacol; 2010 Aug; 160(8):1973-84. PubMed ID: 20649595
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of Cu-64 and Ga-68 Radiolabeled Glucagon-Like Peptide-1 Receptor Agonists as PET Tracers for Pancreatic β cell Imaging.
Bandara N; Zheleznyak A; Cherukuri K; Griffith DA; Limberakis C; Tess DA; Jianqing C; Waterhouse R; Lapi SE
Mol Imaging Biol; 2016 Feb; 18(1):90-8. PubMed ID: 25987465
[TBL] [Abstract][Full Text] [Related]
58. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice.
Kooijman S; Wang Y; Parlevliet ET; Boon MR; Edelschaap D; Snaterse G; Pijl H; Romijn JA; Rensen PC
Diabetologia; 2015 Nov; 58(11):2637-46. PubMed ID: 26254578
[TBL] [Abstract][Full Text] [Related]
59. The Interplay of Glucagon-Like Peptide-1 Receptor Trafficking and Signalling in Pancreatic Beta Cells.
Marzook A; Tomas A; Jones B
Front Endocrinol (Lausanne); 2021; 12():678055. PubMed ID: 34040588
[TBL] [Abstract][Full Text] [Related]
60. Noninvasive Monitoring of Glycemia-Induced Regulation of GLP-1R Expression in Murine and Human Islets of Langerhans.
Buitinga M; Cohrs CM; Eter WA; Claessens-Joosten L; Frielink C; Bos D; Sandker G; Brom M; Speier S; Gotthardt M
Diabetes; 2020 Nov; 69(11):2246-2252. PubMed ID: 32843570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
